Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
09 06 2020
Historique:
received: 28 01 2020
revised: 03 04 2020
accepted: 06 04 2020
entrez: 6 6 2020
pubmed: 6 6 2020
medline: 6 1 2021
Statut: ppublish

Résumé

Cardiac magnetic resonance (CMR) is widely used to assess tissue and functional abnormalities in arrhythmogenic right ventricular cardiomyopathy (ARVC). Recently, a ARVC risk score was proposed to predict the 5-year risk of malignant ventricular arrhythmias in patients with ARVC. However, CMR features such as fibrosis, fat infiltration, and left ventricular (LV) involvement were not considered. The authors sought to evaluate the prognostic role of CMR phenotype in patients with definite ARVC and to evaluate the effectiveness of the novel 5-year ARVC risk score to predict cardiac events in different CMR presentations. A total of 140 patients with definite ARVC were enrolled (mean age 42 ± 17 years, 97 males) in this multicenter prospective registry. As per study design, CMR was performed in all the patients at enrollment. The novel 5-year ARVC risk score was retrospectively calculated using the patient's characteristics at the time of enrollment. During a median follow-up of 5 years (2 to 8 years), the combined endpoint of sudden cardiac death, appropriate implantable cardioverter-defibrillator intervention, and aborted cardiac arrest was considered. CMR was completely negative in 14 patients (10%), isolated right ventricular (RV) involvement was found in 58 (41%), biventricular in 52 (37%), and LV dominant in 16 (12%). During the follow-up, 48 patients (34%) had major events, but none occurred in patients with negative CMR. At Kaplan-Meier analysis, patients with LV involvement (LV dominant and biventricular) had a worse prognosis than those with lone RV (p < 0.0001). At multivariate analysis, the LV involvement, a LV-dominant phenotype, and the 5-year ARVC risk score were independent predictors of major events. The estimated 5-year risk was able to predict the observed risk in patients with lone RV but underestimated the risk in those with LV involvement. Different CMR presentations of ARVC are associated with different prognoses. The 5-year ARVC risk score is valid for the estimation of risk in patients with lone-RV presentation but underestimated the risk when LV is involved.

Sections du résumé

BACKGROUND
Cardiac magnetic resonance (CMR) is widely used to assess tissue and functional abnormalities in arrhythmogenic right ventricular cardiomyopathy (ARVC). Recently, a ARVC risk score was proposed to predict the 5-year risk of malignant ventricular arrhythmias in patients with ARVC. However, CMR features such as fibrosis, fat infiltration, and left ventricular (LV) involvement were not considered.
OBJECTIVES
The authors sought to evaluate the prognostic role of CMR phenotype in patients with definite ARVC and to evaluate the effectiveness of the novel 5-year ARVC risk score to predict cardiac events in different CMR presentations.
METHODS
A total of 140 patients with definite ARVC were enrolled (mean age 42 ± 17 years, 97 males) in this multicenter prospective registry. As per study design, CMR was performed in all the patients at enrollment. The novel 5-year ARVC risk score was retrospectively calculated using the patient's characteristics at the time of enrollment. During a median follow-up of 5 years (2 to 8 years), the combined endpoint of sudden cardiac death, appropriate implantable cardioverter-defibrillator intervention, and aborted cardiac arrest was considered.
RESULTS
CMR was completely negative in 14 patients (10%), isolated right ventricular (RV) involvement was found in 58 (41%), biventricular in 52 (37%), and LV dominant in 16 (12%). During the follow-up, 48 patients (34%) had major events, but none occurred in patients with negative CMR. At Kaplan-Meier analysis, patients with LV involvement (LV dominant and biventricular) had a worse prognosis than those with lone RV (p < 0.0001). At multivariate analysis, the LV involvement, a LV-dominant phenotype, and the 5-year ARVC risk score were independent predictors of major events. The estimated 5-year risk was able to predict the observed risk in patients with lone RV but underestimated the risk in those with LV involvement.
CONCLUSIONS
Different CMR presentations of ARVC are associated with different prognoses. The 5-year ARVC risk score is valid for the estimation of risk in patients with lone-RV presentation but underestimated the risk when LV is involved.

Identifiants

pubmed: 32498802
pii: S0735-1097(20)34933-0
doi: 10.1016/j.jacc.2020.04.023
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2753-2765

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Giovanni Donato Aquaro (GD)

Fondazione Toscana G. Monasterio, Pisa, Italy. Electronic address: aquaro@ftgm.it.

Antonio De Luca (A)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Chiara Cappelletto (C)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Francesca Raimondi (F)

Pediatric Cardiology, Hôpital Necker-Enfants Malades, Paris, France.

Francesco Bianco (F)

Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy.

Nicoletta Botto (N)

Fondazione Toscana G. Monasterio, Pisa, Italy.

Pierluigi Lesizza (P)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Crysanthos Grigoratos (C)

Fondazione Toscana G. Monasterio, Pisa, Italy.

Monia Minati (M)

Cardiology Department, Policlinico Casilino, Rome, Italy.

Matteo Dell'Omodarme (M)

Dipartimento di Fisica, "Enrico Fermi," University of Pisa, Pisa, Italy.

Alessandro Pingitore (A)

Institute of Clinical Physiology, National Council of Research, Pisa, Italy.

Davide Stolfo (D)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Matteo Dal Ferro (MD)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Marco Merlo (M)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Gianluca Di Bella (G)

University of Messina, Messina, Italy.

Gianfranco Sinagra (G)

Cardio-thoraco-vascular Department, University of Trieste, Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH